Work Here?
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Seres Therapeutics develops microbiome-based therapies that use beneficial bacteria to treat diseases, particularly focusing on conditions like Clostridium difficile infection (CDI) and other gastrointestinal disorders. Their approach aims to restore the natural balance of bacteria in the human body, addressing the root causes of these diseases. The company operates from Cambridge, Massachusetts, where it conducts research, clinical trials, and manufacturing. Unlike many competitors, Seres Therapeutics emphasizes a strong commitment to research and development, which allows them to create targeted treatments for unmet medical needs. Their goal is to improve patient outcomes through effective microbiome therapies, generating revenue from the sale of approved treatments and potential licensing agreements.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$254.5M
Above
Industry Average
Funded Over
5 Rounds
Both DFSK and Seres were also awarded coveted honors for their electrification campaigns at IIMS 2025.
CAMBRIDGE, Mass. - Seres Therapeutics, Inc. (NASDAQ:MCRB), a biotechnology firm specializing in live biotherapeutics with a market capitalization of $130 million, has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its clinical development strategy for SER-155, an investigational treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Lisa von Moltke will resign from Seres Therapeutics in March 2025.
CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. MCRB (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As previously announced, based on the Company's existing cash, inclusive of this payment, a projected installment payment from Nestlé Health Science in July 2025 of $25 million (less up to approximately $1.5M in employment-related payments to Nestlé Health Science), transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026. About Seres Therapeutics Seres Therapeutics, Inc. MCRB is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics
Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters.
Find jobs on Simplify and start your career today
Mechanical Engineering
1 Open Roles
Discover companies similar to SERES
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Milpitas, CA, USA
Find jobs on Simplify and start your career today
Mechanical Engineering
1 Open Roles
Discover companies similar to SERES